Assessing of Physicians' Knowledge About International Guidelines of Albumin Use in Patients With Liver Cirrhosis

NCT04242979 | Unknown

• 1 other identifier: HA use in liver cirrhosis
• Study Type: interventional
• Target: 1
• Locations: 0 countries
• Sites: N/A

Brief Summary

Due to shortage of local studies of the adherence of physicians to the guidelines for albumin use among patients with liver cirrhosis so this study aims to assess:

1. 1.Physicians' knowledge on the evidence-based indications for HA use supported by the international guidelines;
2. 2.Whether HA is used in clinical conditions not supported by solid scientific evidence;
3. 3.To formulate the evidence-based indications for HA use supported by the international guidelines and to evaluate effect of distributing these evidence-based indications on physicians' knowledge.

Conditions

Liver Cirrhoses

Keywords

Albumin use in liver cirrhosis

Outcome Measures

Primary Outcomes (1)

• Questionnaire

  The investigators will know physicians' basic mean knowledge score about human albumin use in validated and non validated indications. The score will be from (0-2)

  1 month

Secondary Outcomes (1)

• Questionnaire

  2-3 years

Study Arms (1)

Human albumin use in liver cirrhosis

OTHER

Each participant involved in the study will be assessed for his or her knowledge using (tool I). 5-Data will be collected by personal interview with participants or via fulfilling online questionnaire taking in consideration data confidentiality. 6-Application of the designed evidence based indications for human albumin use supported by the international guidelines will be done by researcher using (tool II). 7-Evaluate the effect of the designed evidence based indications for human albumin use supported by the international guidelines on physicians' knowledge after 1 month using (tool I) in a random sample of those physicians.

Behavioral: Questionnaire about albumin use in liver cirrhosis

Interventions

Questionnaire about albumin use in liver cirrhosis BEHAVIORAL

1. Permission to carry out the study will be obtained from the Faculty's Ethics Committee. 2. To achieve validity and reliability of the tool. It will be reviewed by two experts in the field of the study and necessary modification will be done. 3. A pilot study will be 10% done to test the clarity and feasibility of developed tool. 4. Each participant involved in the study will be assessed for his or her knowledge using (tool I). 5. Data will be collected by personal interview with participants or via fulfilling online questionnaire taking in consideration data confidentiality. 6. Application of the designed evidence based indications for human albumin use supported by the international guidelines will be done by researcher using (tool II). 7. Evaluate the effect of the designed evidence based indications for human albumin use supported by the international guidelines on physicians' knowledge after 1 month using (tool I) in a random sample of those physicians

Human albumin use in liver cirrhosis

Eligibility Criteria

• Age: 26 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Gastroenterology physicians in:
• Al-Rajhi Liver Hospital (Tropical Medicine Department, and Internal Medicine, GIT Unit).
• Police Hospital.
• Health Insurance Hospital.
• Assiut Center for Management of HCV.
• El - Shamla Hospital.
• Al-Eman Hospital.

You may not qualify if:

• Non gastroenterology physicians

Sponsors & Collaborators

• Abdelrahman Salah Eldin Abodief: lead

Related Publications (1)

• Caraceni P, Pavesi M, Baldassarre M, Bernardi M, Arroyo V. The use of human albumin in patients with cirrhosis: a European survey. Expert Rev Gastroenterol Hepatol. 2018 Jun;12(6):625-632. doi: 10.1080/17474124.2018.1460203. Epub 2018 Apr 4.

  PMID: 29611452 BACKGROUND

Central Study Contacts

Abdelrahman Salah Abodief, MBBCh

CONTACT

01003447486; abodief.zeid1234@gmail.com

Ehab Fawzy Moustafa, Professor

CONTACT

01016154222; Ehabmostafa99@yahoo.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SCREENING
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Principal Investigator

Model Details: Tool (I): An interview questionnaire(in English) sheet for the physicians will be carried out evaluating : 1. the use of albumin in validated indications. 2. the prescriptions of albumin for non validated clinical situations. TOOL (II): Designed evidence-based indications for HA use supported by the international guidelines. It includes general information about albumin prescription, mechanism of action of albumin in liver cirrhosis, prevention of PPCD, prevention of renal failure after SBP, diagnosis of HRS, treatment of HRS, other potential clinical indication for albumin.

Study Record Dates

• First Submitted: January 11, 2020
• First Posted: January 27, 2020
• Study Start: April 1, 2020
• Primary Completion: April 1, 2022
• Study Completion: April 1, 2023
• Last Updated: January 27, 2020

Record last verified: 2020-01